StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30128% above fair value
$42.23−0.39 (-0.92%)

Close on Nov 18, 2026Market cap $49.21BP/E 70.4Yield –

Teva Pharmaceutical Industries Anda, Inc. by Quarter

Anda, Inc. — Third-Party Pharmaceutical Distribution Revenues (U.S.) ($M)

Teva Pharmaceutical Industries Anda, Inc.: $401M in Q3 2026, up 2.3% from a year earlier.

Latest, Q3 2026
401
Period ended Sep 30, 2026
Change on a year earlier
+2.3%
392 in Q3 2025
History
34 quarters
Since Q1 2018
Sources
30
Documents cited below

Where the Q3 2026 figure comes from

“currency terms, compared to the third quarter of 2025. Anda revenues from third-party products in the third quarter of 2026 were $401 million, an increase of 2%, compared to the third quarter of 2025, mainly due to highe”

Source: Form 8-K Earnings Release (0001171843-26-007054) ↗

Revenues of Anda, Inc. (Teva's U.S. wholesale distributor of generic, brand, specialty, and OTC pharmaceutical products to independent pharmacies, chains, and clinics). Reported within North America / U.S. through FY2025 and moved to Other Activities in Q1 2026.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAnda, Inc. — Third-Party Pharmaceutical Distribution Revenues (U.S.) ($M)Year on yearSource
Q3 2026Sep 30, 2026401+2.3%Form 8-K Earnings Release (0001171843-26-007054) ↗
Q2 2026Jun 30, 2026413+13.2%Form 8-K Earnings Release (0001171843-26-004974) ↗
Q1 2026Mar 31, 2026378+1.3%Form 8-K Earnings Release (0001171843-26-002796) ↗
Q4 2025Dec 31, 2025-1,130-381.1%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2025Sep 30, 2025392+3.2%Form 8-K Earnings Release (0001171843-25-007000) ↗
Q2 2025Jun 30, 2025365-2.1%Form 10-Q (0001193125-25-169296) ↗
Q1 2025Mar 31, 2025373-2.1%Form 10-Q (0001193125-25-114889) ↗
Q4 2024Dec 31, 2024402+2.0%Form 8-K Earnings Release (0001171843-25-000493) ↗
Q3 2024Sep 30, 2024380+3.5%Form 8-K Earnings Release (0001171843-24-006034) ↗
Q2 2024Jun 30, 2024373-4.8%Form 10-Q (0001193125-24-189924) ↗
Q1 2024Mar 31, 2024381-10.1%Form 10-Q (0001193125-24-134200) ↗
Q4 2023Dec 31, 2023394–Form 8-K Earnings Release (0001171843-25-000493) ↗
Q3 2023Sep 30, 2023367-1.1%Form 10-Q (0001193125-23-274495) ↗
Q2 2023Jun 30, 2023392+27.3%Form 8-K Earnings Release (0001193125-23-201707) ↗
Q1 2023Mar 31, 2023424+24.0%Form 10-Q (0001193125-23-140697) ↗
Q4 2022Dec 31, 20220–SEC Form 10-K (0001193125-25-020826) ↗

Breakdown

What makes up anda, Inc.

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Anda, Inc. ($M), quarterly Q1 2018–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/sub-anda-rev

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?